

Fennec Pharmaceuticals Inc (FRX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/F4689863396EN.html>

Date: May 2021

Pages: 42

Price: US\$ 125.00 (Single User License)

ID: F4689863396EN

Abstracts

Fennec Pharmaceuticals Inc (FRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fennec Pharmaceuticals Inc (Fennec) formerly Adherex Technologies Inc, develops drugs for cancer treatments. The company lead product candidate, Pedmark, anhydrous injection in two Phase III clinical trials for the prevention of cisplatin-induced hearing loss and ototoxicity in children. The company has licensing agreements with Oregon Health & Science University for development of its drug candidates. Fennec is headquartered in Durham, North Carolina, the US.

Fennec Pharmaceuticals Inc Key Recent Developments

Mar 30,2021: Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Nov 16,2020: Fennec Pharmaceuticals announces third quarter 2020 financial results and provides business update

Aug 12,2020: Fennec Pharmaceuticals to participate in upcoming investor conferences

Aug 05,2020: Fennec Pharmaceuticals announces second quarter 2020 financial results and provides business update

May 14,2020: Fennec Pharmaceuticals announces first quarter 2020 financial results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Fennec Pharmaceuticals Inc - Key Facts
Fennec Pharmaceuticals Inc - Key Employees
Fennec Pharmaceuticals Inc - Key Employee Biographies
Fennec Pharmaceuticals Inc - Major Products and Services
Fennec Pharmaceuticals Inc - History
Fennec Pharmaceuticals Inc - Company Statement
Fennec Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Fennec Pharmaceuticals Inc - Business Description
Fennec Pharmaceuticals Inc - Corporate Strategy
Fennec Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Fennec Pharmaceuticals Inc - Strengths
Fennec Pharmaceuticals Inc - Weaknesses
Fennec Pharmaceuticals Inc - Opportunities
Fennec Pharmaceuticals Inc - Threats
Fennec Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to

YTD 2021

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 30, 2021: Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Nov 16, 2020: Fennec Pharmaceuticals announces third quarter 2020 financial results and provides business update

Aug 12, 2020: Fennec Pharmaceuticals to participate in upcoming investor conferences

Aug 05, 2020: Fennec Pharmaceuticals announces second quarter 2020 financial results and provides business update

May 14, 2020: Fennec Pharmaceuticals announces first quarter 2020 financial results and provides business update

Feb 14, 2020: Fennec provides business update and announces fiscal year 2019 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Fennec Pharmaceuticals Inc, Key Facts
Fennec Pharmaceuticals Inc, Key Employees
Fennec Pharmaceuticals Inc, Key Employee Biographies
Fennec Pharmaceuticals Inc, Major Products and Services
Fennec Pharmaceuticals Inc, History
Fennec Pharmaceuticals Inc, Subsidiaries
Fennec Pharmaceuticals Inc, Key Competitors
Fennec Pharmaceuticals Inc, Ratios based on current share price
Fennec Pharmaceuticals Inc, Annual Ratios
Fennec Pharmaceuticals Inc, Annual Ratios (Cont...1)
Fennec Pharmaceuticals Inc, Interim Ratios
Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Fennec Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Fennec Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Fennec Pharmaceuticals Inc, Ratio Charts

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Fennec Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Fennec Pharmaceuticals Inc (FRX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/F4689863396EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F4689863396EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970